Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study

Numerous studies have analysed the clinical efficacies of hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS). However, reports that compare the two HMAs, decitabine and azacitidine, in patients with lower-risk (low and intermediate-1) MDS are limited. We compared 5-day de...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byung-Hyun, Kang, Ka-Won, Jeon, Min Ji, Yu, Eun Sang, Kim, Dae Sik, Choi, Hojoon, Lee, Se Ryeon, Sung, Hwa Jung, Kim, Byung Soo, Choi, Chul Won, Park, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949213/
https://www.ncbi.nlm.nih.gov/pubmed/31913293
http://dx.doi.org/10.1038/s41598-019-56642-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949213/
https://www.ncbi.nlm.nih.gov/pubmed/31913293
http://dx.doi.org/10.1038/s41598-019-56642-1

Ejemplares similares